CAS:61618-27-7Amfenac Sodium Monohydrate

您的位置 : 首页 / Immunology/Inflammation / COX / Amfenac Sodium Monohydrate

Amfenac Sodium Monohydrate 氨芬酸钠一水合物 Cat No. FB07819Cas No. 61618-27-7

Amfenac Sodium Monohydrate is a non-steroidal analgesic anti-inflammatory drug with acetic acid moiety. The IC50 values for COX1 and COX2 is 250 nM and 150 nM, respectively.

规格	价格	促销价格	库存

18817579266

立即询价

咨询

18817579266

立即询价

实验数据

储存液制备
- 1 mg
- 5 mg
- 10 mg
- 1 mM
- 3.3868 mL
- 16.9339 mL
- 33.8678 mL
- 5 mM
- 0.6774 mL
- 3.3868 mL
- 6.7736 mL
- 10 mM
- 0.3387 mL
- 1.6934 mL
- 3.3868 mL
计算器摩尔计算器总药量计算器工作液计算器

技术信息

CAS号

61618-27-7

储存条件

粉末: -20°C 3 年

液体: -80°C 12 月

分子式

C15H14NNaO4

运输

蓝冰

分子量

295.27

别名

溶解度

DMSO	58.0 mg/mL (196.4 mM)
Ethanol	4.0 mg/mL (13.5 mM)

动物实验配方

靶点数据

生物活性

靶点 COX2

IC50:150nM COX1

IC50:250nM
描述Amfenac Sodium Monohydrate is a COX-2 (cyclooxygenase-2) inhibitor. Amfenac affected both COX-2 transfected and non-transfected uveal melanoma cells in terms of their proliferation rates as well as their suppressive effects on macrophage cytotoxic activity^[3]. Treatment of UM (uveal melanoma) cell lines with amfenac prior to radiation led to a marked reduction in proliferation rates. There appears to be a radioprotective effect of amfenac on human fibroblasts^[4]. 5×10-4 M Amfenac Sodium Hydrate inhibits the release of the enzyme 35.3 and 16.3% in the presence of 10-8, and 10-7 M FMLP, respectively. Addition of 10-4 M Amfenac Sodium Hydrate causes 28.3% inhibition of aggregation of polgmorphonuclear leukocgtes (PMNs) during incubation for 16 min with 10-8 M FMLP^[5]. Moreover, Amfenac treatment significantly inhibited VEGF-induced tube formation and proliferation by EC. Amfenac treatment significantly reduced retinal prostanoid production and NV (neovascularization) in OIR^[6].

靶点	Description	IC50
COX2		IC50:150nM
COX1		IC50:250nM